Abstract 6061: Dual PD-L1 blockade and VEGF-A neutralization with the bispecific antibody BNT327/PM8002 shows potent antitumor activity in preclinical models
Bibliographic record
Abstract
Abstract The combined blockade of the PD-1/PD-L1 checkpoint and VEGF-A driven angiogenesis has been shown to reduce immune suppression in the tumor microenvironment, to enhance antitumor immune responses, and exhibit improved antitumor activity compared to each individual treatment. BNT327 (also known as PM8002) is an investigational bispecific antibody (bsAb) composed of a bivalent Fc-silenced anti-VEGF-A IgG1 antibody fused at its C-terminus to two humanized anti-PD-L1 single-domain VHH antibodies. By simultaneously targeting PD-L1 and VEGF-A, BNT327 is designed to combine the two complementary functions of amplifying pre-existing immune responses and anti-angiogenesis. Here, we report preclinical studies characterizing the functional activity of BNT327 in vitro and antitumor activity in vivo. BNT327 bound with high affinity (i.e., nanomolar or subnanomolar KD) to recombinant human PD-L1 and VEGF-A, as shown by biolayer interferometry. In cell-based bioluminescent reporter assays, BNT327 inhibited PD-L1/PD-1 signaling and VEGF-A/VEGFR2 signaling with subnanomolar EC50 values. In mixed lymphocyte reaction assays using human PBMCs and allogeneic monocyte-derived dendritic cells, BNT327 and the parental anti-PD-L1 VHH dose-dependently increased IL-2 and IFN-γ secretion. Furthermore, BNT327 dose-dependently enhanced CD8+ T-cell mediated tumor-cell killing in an antigen-specific cytotoxicity assay in vitro, with the effects being comparable to those of PD-L1 blockade by atezolizumab. In vivo, a BNT327 surrogate bsAb targeting human PD-L1 and mouse VEGF-A exhibited dose-dependent antitumor activity in human PD-L1 knock-in mice bearing syngeneic human PD-L1-expressing CT26 tumors. Tumor growth inhibition was superior to individual treatments with PD-L1 blockade (parental anti-PD-L1 or atezolizumab) or with anti-VEGF-A. Furthermore, BNT327 showed antitumor activity in several xenograft models, including A375 melanoma cells, NCI-H1975 lung carcinoma cells, LoVo colon carcinoma cells, and MDA-MB-231 breast carcinoma cells. Antitumor activity was dose-dependent where tested, and superior to single PD-1 (pembrolizumab) or PD-L1 (atezolizumab) checkpoint inhibitor treatment. In conclusion, BNT327 inhibits PD-1/PD-L1 signaling and VEGF-A/VEGFR2 signaling in vitro and shows potent antitumor activity in vivo both in syngeneic and xenograft models. The safety and efficacy of BNT327 as a monotherapy or in combination is being investigated in multiple clinical trials in patients with solid tumors, including Phase II and Phase III trials investigating the combination with chemotherapeutic agents in triple-negative breast cancer and lung cancer. Citation Format: Xiaoniu Miao, Yifeng Xu, Shaogang Peng, Weifeng Huang, Junying Chen, Maren Köhne, Andrea Imle, Alexander Muik, Özlem Türeci, Ugur Sahin, Andy Tsun, Yi Luo. Dual PD-L1 blockade and VEGF-A neutralization with the bispecific antibody BNT327/PM8002 shows potent antitumor activity in preclinical models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6061.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".